目的 探寻双石通淋胶囊联合特拉唑嗪治疗慢性前列腺炎患者的临床疗效。方法 选取2022年1月—2024年12月中国人民解放军海军青岛特勤疗养中心收治的120例慢性前列腺炎患者，依据治疗方式的差异分为对照组和治疗组，每组各60例。对照组患者口服盐酸特拉唑嗪片，2 mg/次，每晚各1次。治疗组患者在对照组方案基础上口服双石通淋胶囊，4粒/次，每天3次。两组患者均连续治疗4周。观察两组的临床疗效，比较两组治疗前后美国国立卫生研究院慢性前列腺炎症状评分指数（NIH-CPSI）评分、尿流动力学指标和血清炎症相关指标的变化情况。结果 治疗后，治疗组总有效率是98.33%，显著高于对照组的85.00%（P＜0.05）。治疗后，两组NIH-CPSI较同组治疗前显著降低（P＜0.05）；治疗后治疗组NIH-CPSI低于对照组（P＜0.05），两组国际勃起功能指数-5（IIEF-5）评分对比无显著的差异。治疗后，两组平均尿流率（AFR）、最大尿流率（MFR）较前显著升高，而膀胱残余尿量（PVR）较前显著降低（P＜0.05）；治疗后治疗组AFR、MFR高于对照组，PVR值低于对照组（P＜0.05）。治疗后，两组血清肿瘤坏死因子-α（TNF-α）、白细胞介素-10（IL-10）较前显著降低，血清白细胞介素-2（IL-2）水平升高（P＜0.05）；治疗后，治疗组患者血清TNF-α、IL-10低于对照组，IL-2水平高于对照组（P＜0.05）。结论 双石通淋胶囊联合特拉唑嗪治疗慢性前列腺炎患者具有较好的临床疗效，可缓解临床不适症状，改善尿流动力学与机体炎症相关指标，安全性尚可。

Objective To explore the clinical efficacy of Shuangshi Tonglin Capsules combined with terazosin in treatment of patients with chronic prostatitis. Methods A total of 120 patients with chronic prostatitis admitted to the Qingdao Special Service Convalescent Center of the People’s Liberation Army Navy from January 2022 to December 2024 were selected and divided into control group and treatment group according to differences in treatment methods, with 60 cases in each group. Patients in control group were orally administered Terazosin Hydrochloride Tablets, 2 mg each time, once a night. Patients in treatment group orally took Shuangshi Tonglin Capsules on the basis of control group’s regimen, 4 capsules each time, 3 times daily. Both groups of patients were treated continuously for 4 weeks. Results After treatment, the total effective rate of treatment group was 98.33%, significantly higher than 85.00% of control group (P < 0.05). After treatment, NIH-CPSI in both groups was significantly lower than that before treatment in the same group (P < 0.05). After treatment, the NIH-CPSI in treatment group was lower than that in control group (P < 0.05), and there was no significant difference in IIEF-5 score between two groups. After treatment, the average urinary flow rate (AFR) and maximum urinary flow rate (MFR) in both groups were significantly increased compared with before, but the residual urine volume of the bladder (PVR) was significantly decreased compared with before (P < 0.05). After treatment, the AFR and MFR in treatment group were higher than those in control group, but the PVR value was lower than that in control group (P < 0.05). After treatment, the levels of serum TNF-α and IL-10 in both groups decreased significantly compared with before, and the level of serum IL-2 increased (P < 0.05). After treatment, the levels of serum TNF-α and IL-10 in treatment group were lower than those in control group, and the level of IL-2 was higher than that in control group (P < 0.05). Conclusion Shuangshi Tonglin Capsules combined with terazosin have a good clinical effect in treatment of patients with chronic prostatitis, and can relieve clinical discomfort symptoms, improve urodynamic and inflammation-related indicators of the body, and the safety is acceptable.

R983